Samsung Biologics eyes early May RFP for 2016 listing

By Jonathan Breen
28 Apr 2016

Samsung Biologics Co will send out a request for proposals next week for its 2016 IPO, expected to fetch over W3tr ($2.6bn), a source close to the situation told GlobalCapital Asia.

Following the RFP the company, which is Samsung’s drug manufacturing arm, is planning to hire more than two lead managers, said the source.

The issuer, which is expected to have a market capitalisation of around W10tr, is looking to list on the Kospi in the fourth quarter of this ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial